Ultragenyx Pharmaceutical (United States)

Ultragenyx Pharmaceutical is a biopharmaceutical company committed to developing treatments for rare and ultra-rare genetic diseases. Based in Novato, California, the company developed Crysvita (burosumab) for X-linked hypophosphatemia, Mepsevii for MPS VII, and Dojolvi for long-chain fatty acid oxidation disorders. Ultragenyx’s rare disease expertise transforms lives of patients with devastating inherited conditions.